Human CHO-K1/MC3/Gα15 Stable Cell Line

[CAT#: NCL20120085CR]

MC3 Melanocortin Receptor Stable Cell Line

Species:: Human

Applications:: GPCR Screening

Cell Types:: Other Cells

Certificate of Analysis Lookup
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number

Request Pricing

Inquiry

Product Overview

Description

The melanocortin receptor 3 is Gs-coupled GPCRs expressed in brain, placental, and gut tissues but not in melanoma cells or in the adrenal gland. MC3 receptor knockouts exhibit a metabolic syndrome. At 4-6 months old, MC3 receptor knockout mice show increased fat mass, reduced lean mass and a higher feed efficiency, with normal metabolic rates. MC3 receptor knockout mice are hyperleptinaemic and males are often mildly hyperinsulinaemic.

Cell Types

Other Cells

Applications

GPCR Screening

Research Areas

GPCR; Neural Cell

Species

Human

Properties

Size

>1x10^6 Cells

Form

Frozen cells

Culture Medium

Ham's F12, 10% FBS, 200 μg/ml Zeocin, 100 μg/ml Hygromycin B

Freeze Medium

45% culture medium, 45% FBS, 10% DMSO

Receptor

MC3

Family

Melanocortin receptor

Strain

MC3/Gα15 Cell Line

Cell Purity

>95%

Shipping

Dry ice

Storage

Liquid nitrogen immediately upon delivery

Handling Advice

Avoid inhalation. Avoid contact with eyes, skin, and clothing. Avoid prolonged or
repeated exposure.

Research Use Only

For research use only, not for diagnostic or therapeutic use.

Warnings

Store under recommended storage conditions (liquid nitrogen). Do not expose to high temperature. After expiration, discard all remaining reagents.

Target Details

Target

MC3

Official Name

MC3

Alternative Names

MC3R; MC3; MC3-R; melanocortin 3 receptor; BMIQ9; OB20; OQTL

Gene ID

4159(Human)

Uniprot ID

P41968(Human)

References

1. Watanabe, H., Matsushita, N., Shimizu, Y., Iikuni, S., Nakamoto, Y., Togashi, K., & Ono, M. (2019). Synthesis and characterization of a novel 18 F-labeled 2, 5-diarylnicotinamide derivative targeting orexin 2 receptor. MedChemComm, 10(12), 2126-2130.

Publications